Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antiparkinsonian

or [[:Category:Antisecretory_agents|Gastric acid suppressant]]

Use the filters below to narrow your results.

Amantadine (1) · Apomorphine (1) · Benztropine (1) · Biperiden (1) · Bromocriptine (1) · Cabergoline (1) · Carbidopa/levodopa (1) · Entacapone (1) · Esomeprazole (1) · Famotidine (1) · Levodopa (1) · Omeprazole (1) · Opicapone (1) · Pantoprazole (1) · Rasagiline (1) · Rotigotine (1) · Safinamide (1) · Selegiline (1) · Tolcapone (1) · Trihexyphenidyl (1)

None (1) · Akineton (1) · Apokyn (1) · Artane (1) · Azilect (1) · Cogentin (1) · Comtan (1) · Dostinex (1) · Eldepryl (1) · Neupro (1) · Nexium, Nexium 24HR (OTC) (1) · Ongentys (1) · Parlodel (1) · Pepcid, Pepcid AC, Pepcid Complete (1) · Prilosec, Losec, Zegerid (1) · Protonix (1) · Sinemet (1) · Symmetrel (1) · Tasmar (1) · Xadago (1)

Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · Irreversible selective MAO-B inhibitor (2) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · Non-selective dopamine receptor agonist (1) · Once-daily COMT inhibitor (1) · Peripheral COMT inhibitor (1) · Selective M1 muscarinic antagonist (1) · '"`UNIQ--vote-000000D8-QINU`"' Recovery of acid output requires synthesis of new pump enzyme. CYP2C19 substrate; PGx genotype substantially affects exposure and efficacy'"`UNIQ--ref-000000D9-QINU`"'. (1) · '"`UNIQ--vote-00000117-QINU`"' Compared with omeprazole, pantoprazole has a more linear pharmacokinetic profile and is metabolized predominantly via CYP2C19 with CYP3A4 contribution; less CYP2C19-driven drug interaction with clopidogrel than omeprazole'"`UNIQ--ref-00000118-QINU`"'. (1) · '"`UNIQ--vote-00000255-QINU`"' Less potent and shorter-acting than PPIs but with faster on-effect; suitable for on-demand acid suppression. Largely renally cleared; dose-adjust in renal impairment to avoid CNS effects (confusion in elderly)'"`UNIQ--ref-00000256-QINU`"'. (1) · '"`UNIQ--vote-000008E1-QINU`"' Like omeprazole, it is an acid-activated prodrug that covalently and irreversibly binds the H+/K+ ATPase. CYP2C19 PGx remains clinically relevant for both'"`UNIQ--ref-000008E2-QINU`"'. (1)

None (16) · 20 mg PO once daily 30-60 minutes before breakfast (1) · 20 mg PO twice daily, or 40 mg at bedtime (1) · 20-40 mg PO once daily, 30-60 minutes before breakfast (1) · 40 mg PO or IV once daily (1)

None (16) · 10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV (1) · 10, 20, 40 mg delayed-release capsules and tablets; 2 mg/mL oral suspension; immediate-release combo with sodium bicarbonate (Zegerid) (1) · 20 mg, 40 mg delayed-release tablets; 40 mg IV vial; oral suspension 40 mg/packet (1) · 20, 40 mg delayed-release capsules; 2.5, 5, 10, 20, 40 mg oral suspension packets; 20, 40 mg IV (1)

None (16) · 160 mg/d (Zollinger-Ellison); 80 mg/d for routine indications (1) · 40 mg/d typical; up to 240 mg/d for Zollinger-Ellison (2) · 40 mg/d typical; up to 360 mg/d for Zollinger-Ellison (1)

None (16) · IV (4) · Oral (4)

None (16) · 1 hour PO; minutes IV (1) · 2-3 hours per dose; full acid suppression after 3-5 days (1) · Acid suppression within hours; full effect after 3-5 days of dosing (1) · Symptom relief 1-4 days; full acid suppression after 3-5 days of dosing (1)

None (16) · 24+ hours (irreversible enzyme binding) (1) · 24-72 hours per dose (irreversible enzyme binding) (1) · 24-72 hours per dose (irreversible enzyme binding; effect outlasts plasma exposure) (1) · 6-12 hours (1)

None (16) · 0.5-1.5 hours (plasma); pharmacodynamic effect persists 24+ hours'"`UNIQ--ref-000000DE-QINU`"' (1) · 2.5-3.5 hours; longer in renal impairment'"`UNIQ--ref-0000025B-QINU`"' (1) · ~1 hour (plasma); pharmacodynamic effect persists 24+ hours'"`UNIQ--ref-0000011D-QINU`"' (1) · ~1.5 hours (plasma); pharmacodynamic effect 24+ hours via target turnover'"`UNIQ--ref-000008E8-QINU`"' (1)

None (16) · 30-40% (oral; increases with repeated dosing as gastric pH rises)'"`UNIQ--ref-000000DF-QINU`"' (1) · 40-45% (oral; not significantly affected by food)'"`UNIQ--ref-0000025C-QINU`"' (1) · ~64-90% (oral; increases at higher doses and with multi-day dosing)'"`UNIQ--ref-000008E9-QINU`"' (1) · ~77% (oral; not affected by food or antacids)'"`UNIQ--ref-0000011E-QINU`"' (1)

None (16) · Generally considered safe; widely used in obstetric reflux.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe; widely used. Cleared in lactation at low levels.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Widely used in obstetric reflux; reassuring data.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Widely used in pregnancy; meta-analyses do not show increased malformation risk.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

None (16) · OTC (10-20 mg) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1) · OTC (20 mg) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1) · OTC (20 mg, 14-day course) and [[USLegal:Prescription only|Rx-only]] (higher and longer durations) in US (1) · [[USLegal:Prescription only|Rx-only]] in US (1)